Company
Boston
Every investor coverage indicates participated in a round Harvard Medical School raised.
Companies Harvard Medical School acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Hadine Joffe | Paula A. Johnson Associate Professor of Psychiatry in the Field of Women’s Health | Brandon BioCatalyst portfolio |
| Dr Jagmeet P. Singh | Professor of Medicine (former) | Brandon BioCatalyst, Brandon Capital |
| Jarrod Marto | Associate Professor | Brandon Capital portfolio |
| Sara Buhrlage | Associate Professor | Brandon Capital portfolio |
Stories naming Harvard Medical School. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
ANDHealth's blog interviews Australis Scientific's founder about its wearable therapy for bladder conditions, its years in ANDHealth programs, and plans to scale the device at home and abroad.
University of Melbourne researchers describe a faster acoustic bioprinting method for human-like tissue; PhD candidate Callum Vidler's project recently won a $199,482 seed grant via the national AEA pilot program.
Vaxxas hires former Pfizer medical executive Dr Rochelle Chaiken as its chief medical officer; the announcement also recounts the biotech's founding financing and later rounds.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·labonline.com.au·SmartCompany·SmartCompany·labonline.com.au
Cardiac pacing company EBR Systems says its SOLVE-CRT trial hit its safety and efficacy goals early, keeping a 2024 US approval bid on course; the article also recalls its 2021 ASX listing.
Biotech startup Entact Bio has launched with an $81 million Series A funding its Encompass platform, which designs molecules that enhance protein function, backed by Qiming Venture Partners USA, venBio Partners and others.
QUE Oncology is beginning placebo-controlled Phase II trials of its drug Q-122 at US hospitals, testing it against hot flashes in breast cancer patients on endocrine therapy, with its CEO and a lead investigator quoted.
Sunshine Heart announced Dr Richard Lin will step down from its board at the November 2007 AGM, with Three Arch Partners nominating Dr Conrad Wang to stand for election in his place.